These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 34236111)

  • 21. Correlation between serum homocysteine concentration and severity of mitral valve disease in dogs.
    Lee CM; Jeong DM; Kang MH; Kim SG; Han JI; Park HM
    Am J Vet Res; 2017 Apr; 78(4):440-446. PubMed ID: 28345991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    Vet Clin Pathol; 2013 Jun; 42(2):196-206. PubMed ID: 23614733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease.
    McManamey AK; DeFrancesco TC; Meurs KM; Papich MG
    J Vet Intern Med; 2023; 37(6):2003-2010. PubMed ID: 37776546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of concurrent lower respiratory tract disease on point-of-care lung ultrasound in small-breed dogs with myxomatous mitral valve disease.
    Lam MC; Lin CH; Lo PY; Wu HD
    J Vet Intern Med; 2022 May; 36(3):1075-1081. PubMed ID: 35475522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pulmonary-vein-to-pulmonary-artery ratio can be utilized to evaluate myxomatous mitral valve disease progression in dogs.
    Kim MS; Kim J; Seo MW; Park C
    Am J Vet Res; 2024 Jul; 85(7):. PubMed ID: 38663446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and risk factors for atrial fibrillation in dogs with myxomatous mitral valve disease.
    Guglielmini C; Goncalves Sousa M; Baron Toaldo M; Valente C; Bentivoglio V; Mazzoldi C; Bergamin I; Drigo M; Poser H
    J Vet Intern Med; 2020 Nov; 34(6):2223-2231. PubMed ID: 33031593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutrophil-to-lymphocyte ratio is increased in dogs with acute congestive heart failure secondary to myxomatous mitral valve disease compared to both dogs with heart murmurs and healthy controls.
    DeProspero DJ; Hess RS; Silverstein DC
    J Am Vet Med Assoc; 2023 Nov; 261(11):1-8. PubMed ID: 37406992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Longitudinal Outcome Of Canine (K9) myxomatous mitral valve disease (LOOK-Mitral registry): Baseline characteristics.
    Franchini A; Borgarelli M; Abbott JA; Menciotti G; Crosara S; Häggström J; Lahmers S; Rosenthal S; Tyrrell W
    J Vet Cardiol; 2021 Aug; 36():32-47. PubMed ID: 34062479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study.
    Hezzell MJ; Boswood A; López-Alvarez J; Lötter N; Elliott J
    J Vet Cardiol; 2017 Aug; 19(4):325-338. PubMed ID: 28734620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating MiR-30b-5p is upregulated in Cavalier King Charles Spaniels affected by early myxomatous mitral valve disease.
    Bagardi M; Ghilardi S; Zamarian V; Ceciliani F; Brambilla PG; Lecchi C
    PLoS One; 2022; 17(7):e0266208. PubMed ID: 35816500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biopterin status in dogs with myxomatous mitral valve disease is associated with disease severity and cardiovascular risk factors.
    Reimann MJ; Häggström J; Mortensen A; Lykkesfeldt J; Møller JE; Falk T; Olsen LH
    J Vet Intern Med; 2014; 28(5):1520-6. PubMed ID: 25274442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Untargeted metabolomic profiling of dogs with myxomatous mitral valve disease and congestive heart failure shows metabolic differences associated with the presence of cardiac cachexia.
    Freeman LM; Rush JE; Karlin ET
    Am J Vet Res; 2023 Dec; 84(12):. PubMed ID: 38041949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dietary intervention reduces left atrial enlargement in dogs with early preclinical myxomatous mitral valve disease: a blinded randomized controlled study in 36 dogs.
    Li Q; Heaney A; Langenfeld-McCoy N; Boler BV; Laflamme DP
    BMC Vet Res; 2019 Nov; 15(1):425. PubMed ID: 31775756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of serum cystatin C concentration in dogs with myxomatous mitral valve disease.
    Iwasa N; Kumazawa R; Nomura S; Shimizu M; Iwata M; Hara M; Kawabe M; Kobatake Y; Takashima S; Nishii N
    J Vet Intern Med; 2023 Mar; 37(2):412-419. PubMed ID: 36852471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serotonin concentrations in platelets, plasma, mitral valve leaflet, and left ventricular myocardial tissue in dogs with myxomatous mitral valve disease.
    Cremer SE; Singletary GE; Olsen LH; Wallace K; Häggström J; Ljungvall I; Höglund K; Reynolds CA; Pizzinat N; Oyama MA
    J Vet Intern Med; 2014; 28(5):1534-40. PubMed ID: 25146933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteomics reveals plasma protein SERPINH1 as a potential diagnostic biomarkers for myxomatous mitral valve disease stage B2.
    Zhou Q; Wu Z; Li L; Zhou H; Chen Y; Guo S; Guo Y; Ma X; Zhang J; Feng W; Cui X; Qiu C; Xu M; Deng G
    J Proteomics; 2023 Jun; 282():104924. PubMed ID: 37146676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Echocardiographic Estimates of Right Ventricular Systolic Function in Dogs with Myxomatous Mitral Valve Disease.
    Chapel EH; Scansen BA; Schober KE; Bonagura JD
    J Vet Intern Med; 2018 Jan; 32(1):64-71. PubMed ID: 29224256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incremental predictive value of echocardiographic indices of right ventricular function in the assessment of long-term prognosis in dogs with myxomatous mitral valve disease.
    Morita T; Nakamura K; Osuga T; Takiguchi M
    J Vet Cardiol; 2022 Feb; 39():51-62. PubMed ID: 34979482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytokine expression in peripheral blood mononuclear cells of dogs with mitral valve disease.
    Mavropoulou A; Guazzetti S; Borghetti P; De Angelis E; Quintavalla C
    Vet J; 2016 May; 211():45-51. PubMed ID: 27033593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma and serum serotonin concentrations and surface-bound platelet serotonin expression in Cavalier King Charles Spaniels with myxomatous mitral valve disease.
    Cremer SE; Kristensen AT; Reimann MJ; Eriksen NB; Petersen SF; Marschner CB; Tarnow I; Oyama MA; Olsen LH
    Am J Vet Res; 2015 Jun; 76(6):520-31. PubMed ID: 26000599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.